EU approves Ruconest for HAE
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum is planning to launch Ruconest (conestat alfa) in Germany, the UK, Sweden, Finland and Denmark following today's news that the European Commission has approved the recombinant human C1 inhibitor to treat acute attacks of hereditary angioedema. Pharming, the Dutch biotech company that developed the drug, is now entitled to a €5 million milestone payment from its marketing and distribution partner